Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
A 
Agilent Technologies Inc (A)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: A (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $138.83
1 Year Target Price $138.83
| 9 | Strong Buy |
| 2 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.44% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 36.06B USD | Price to earnings Ratio 29.72 | 1Y Target Price 138.83 |
Price to earnings Ratio 29.72 | 1Y Target Price 138.83 | ||
Volume (30-day avg) 20 | Beta 1.24 | 52 Weeks Range 96.23 - 153.19 | Updated Date 09/16/2025 |
52 Weeks Range 96.23 - 153.19 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 0.78% | Basic EPS (TTM) 4.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-27 | When After Market | Estimate 1.37 | Actual 1.37 |
Profitability
Profit Margin 17.97% | Operating Margin (TTM) 23.19% |
Management Effectiveness
Return on Assets (TTM) 8.35% | Return on Equity (TTM) 19.88% |
Valuation
Trailing PE 29.72 | Forward PE 20.75 | Enterprise Value 37490158644 | Price to Sales(TTM) 5.31 |
Enterprise Value 37490158644 | Price to Sales(TTM) 5.31 | ||
Enterprise Value to Revenue 5.52 | Enterprise Value to EBITDA 20.86 | Shares Outstanding 283500000 | Shares Floating 282494000 |
Shares Outstanding 283500000 | Shares Floating 282494000 | ||
Percent Insiders 0.29 | Percent Institutions 92.65 |
Upturn AI SWOT
Agilent Technologies Inc
Company Overview
History and Background
Agilent Technologies Inc. was founded in 1999 as a spin-off from Hewlett-Packard. It inherited HP's test and measurement, chemical analysis, life sciences, and healthcare businesses. Since its inception, Agilent has focused on innovation in these areas and expanded its portfolio through strategic acquisitions.
Core Business Areas
- Life Sciences and Applied Markets Group (LSAG): Provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products. This segment focuses on applications in pharmaceuticals, diagnostics, environmental and food testing, and academia.
- Diagnostics and Genomics Group (DGG): Offers solutions that include reagents, instruments, software, and services for clinical and pathology labs. This segment focuses on cancer diagnostics, next-generation sequencing, and genetic testing.
- Agilent CrossLab Group (ACG): Provides a broad portfolio of lab-wide services and consumables such as columns and sample preparation products to support customers' laboratory operations and productivity.
Leadership and Structure
Agilent Technologies Inc. is led by President and CEO Padraig McDonnell. The organizational structure comprises business segments with centralized support functions such as finance, human resources, and legal.
Top Products and Market Share
Key Offerings
- Liquid Chromatography-Mass Spectrometry (LC/MS): Agilent's LC/MS systems are used for analyzing chemical compounds in various applications. Competitors include Thermo Fisher Scientific (TMO), Waters Corporation (WAT), and SCIEX. Market share data varies by region and application, but Agilent is generally considered a leading player. Revenue is a significant portion of the LSAG business, but is not publicly disclosed as a separate figure.
- Gas Chromatography (GC): Agilent's GC systems are widely used in environmental monitoring, food safety, and chemical analysis. Competitors include Thermo Fisher Scientific (TMO) and PerkinElmer (PKI). Agilent is a market leader in GC, with market share varying by specific region and application. Like LC/MS, specific revenue contribution is not disclosed.
- Genomics Solutions: Agilent offers microarray platforms, next-generation sequencing (NGS) tools and services. Competitors in the genomics space include Illumina (ILMN) and Thermo Fisher Scientific (TMO). Agilent holds a significant share of the microarray market but competes fiercely in NGS.
Market Dynamics
Industry Overview
The analytical and life science instrumentation market is characterized by technological advancements, increasing regulatory requirements, and growing demand for precision and accuracy. It is influenced by trends in pharmaceuticals, diagnostics, environmental monitoring, and food safety.
Positioning
Agilent is positioned as a leading provider of high-end analytical instrumentation and related services, known for its innovation, quality, and comprehensive solutions. Its competitive advantages include its broad product portfolio, strong brand reputation, and global service network.
Total Addressable Market (TAM)
The total addressable market for analytical and life science instrumentation is estimated to be several tens of billions of USD. Agilent is well-positioned to capture a significant portion of this market due to its diverse product offerings and established market presence.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Broad Product Portfolio
- Global Service Network
- Technological Innovation
- Experienced Leadership
Weaknesses
- High Product Prices
- Dependence on Specific Industries
- Potential for Disruption by Emerging Technologies
Opportunities
- Expanding into Emerging Markets
- Developing New Diagnostic and Genomic Solutions
- Increasing Focus on Services and Consumables
- Leveraging Data Analytics and AI
- Strategic Acquisitions to Expand Capabilities
Threats
- Intense Competition
- Economic Downturns
- Changes in Regulatory Environment
- Technological Obsolescence
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- TMO
- WAT
- ILMN
- PKI
Competitive Landscape
Agilent enjoys a strong position owing to its diverse portfolio and reputation for quality. However, competitors like Thermo Fisher Scientific have a broader range of offerings due to larger size, while Illumina dominates the genomics market. Agilent's success hinges on continued innovation and strategic acquisitions in key growth areas.
Major Acquisitions
Resolution Bioscience
- Year: 2021
- Acquisition Price (USD millions): 550
- Strategic Rationale: Expanded Agilent's capabilities in next-generation sequencing-based cancer diagnostics.
BioTek Instruments
- Year: 2019
- Acquisition Price (USD millions): 1050
- Strategic Rationale: Expanded Agilent's cell analysis portfolio, complementing its existing liquid chromatography and mass spectrometry technologies.
Growth Trajectory and Initiatives
Historical Growth: Data needed from a financial data provider to discuss Agilent Technologies Inc's growth trends over the past years.
Future Projections: Data needed from a financial data provider to provide projections for Agilent Technologies Inc's future growth based on analyst estimates.
Recent Initiatives: Recent initiatives include expanding its presence in the cell analysis market through acquisitions and collaborations, introducing innovative products in genomics and diagnostics, and enhancing its service and support offerings.
Summary
Agilent Technologies is a strong player in the analytical and life sciences instrument market with a broad portfolio and a good reputation. The company is investing in growth areas like diagnostics and genomics through strategic acquisitions. However, Agilent must carefully navigate intense competition and technological changes. They also need to be aware of economic conditions in the marketplace.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Agilent Technologies Inc. Investor Relations
- Industry Reports
- Financial News Outlets
Disclaimers:
The data provided is based on available information and estimates. Actual results may vary. This analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agilent Technologies Inc
Exchange NYSE | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 1999-11-18 | CEO, President & Director Mr. Padraig McDonnell | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18000 | Website https://www.agilent.com |
Full time employees 18000 | Website https://www.agilent.com | ||
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies. The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.